Apixaban for Extended Thromboprophylaxis After Oncologic Resection: Outcomes and Cost Analysis.
Kathrine KellyLauren M BlanckKelvin LimAlexa NormanCharlaine V RobertoM Mura AssifiG Paul WrightMathew ChungPublished in: The American surgeon (2023)
Apixaban therapy for ETP did not produce a statistically significant reduction in VTE events in our patients. Future studies should include more patients in a prospective multicenter trial.
Keyphrases
- end stage renal disease
- venous thromboembolism
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- atrial fibrillation
- randomized controlled trial
- clinical trial
- type diabetes
- metabolic syndrome
- adipose tissue
- insulin resistance
- cross sectional
- rectal cancer
- minimally invasive
- double blind